Results for:(80 found)
Mar 6, 2013 11:59AM on Top StocksBy TheStreet Staff

As it strives to increase its product pipeline, the drug company could make a takeover bid -- or entertain a takeover offer.

Mar 4, 2013 1:00PM on Top StocksBy MSN Money Partner

Bristol-Myers is downgraded to 'neutral,' and Gap is initiated with an 'underperform.'

Jan 24, 2013 1:33PM on Top StocksBy MSN Money Partner

Stocks manage to withstand a disappointment from the biggest name in technology on the strength of some other encouraging earnings reports.

Jan 14, 2013 3:55PM on Top StocksBy Minyanville.com

The pharmaceutical company filed with the FDA to sell its experimental treatment albiglutide.

Dec 31, 2012 2:22PM on Top StocksBy MSN Money Partner

Stocks rally ahead of President Obama's statement on the fiscal cliff negotiations.

Dec 31, 2012 11:15AM on Top StocksBy MSN Money Partner

Alon USA Energy is initiated with a 'buy,' and Ferro is downgraded to 'neutral.'

Tags: BMYFB
Dec 27, 2012 11:51AM on Top StocksBy Minyanville.com

Biogen Idec, Pfizer, Bristol-Myers and Celgene are among companies awaiting US approval of key treatments.

Dec 19, 2012 9:26AM on Top StocksBy Stock Traders Daily

With the help of an imaging agent, the pharma is pursuing what it hopes will be a blockbuster drug.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More